(688806)"ZHUHAI TRINOMAB PHARMACEUTICAL CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 688806 · · 13 pages · Chinese
Summary by 6ix AI
The report indicates that the company has experienced significant revenue growth compared to the previous year, attributed to the commercialization of its first product. However, the company continues to report substantial losses, although these have narrowed compared to the same period last year. The report also highlights a decrease in research and development expenses relative to revenue, reflecting a strategic shift in resource allocation.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Zhuhai Trinomab Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhuhai Trinomab Pharmaceutical
- (688806)"ZHUHAI TRINOMAB PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026
- (688806)"ZHUHAI TRINOMAB PHARMACEUTICAL CO., LTD."Announcement on Election of Employee Representative Director for the 2nd Board of Directors
- (688806)"ZHUHAI TRINOMAB PHARMACEUTICAL CO., LTD."Announcement on Completion of Election of New Board of Directors and Appointment of Senior Executive and Securities Affairs Representative
- (688806)"ZHUHAI TRINOMAB PHARMACEUTICAL CO., LTD."Announcement on Appointment of Board Secretary
Follow Zhuhai Trinomab Pharmaceutical into a list and get an email when it puts out news.
Follow Zhuhai Trinomab Pharmaceutical